Skip to main content
Fig. 1 | BMC Medical Research Methodology

Fig. 1

From: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC

Fig. 1

Kaplan-Meier estimate of the progression-free survival (PFS) of metastatic NSCLC patients treated with nivolumab in the clinical trial versus real-world. The progression-free survival time was calculated from randomization date to first progression in clinical trial patients and from start of nivolumab treatment to first progression in real-world patients

Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us